Abstract
Ammonia is a neurotoxic molecule that causes cerebral edema and encephalopathy. Ammonia is either produced in excess or poorly purified during severe hepatic insufficiency, poisoning, infection, and inborn errors of metabolism. During continuous renal replacement therapy, ammonia clearance is determined by the dialysate flow rate and the dialyzer surface area. Extra-renal blood purification for ammonia clearance has been studied in neonates with urea cycle disorders. Prognostic factors affecting patient outcome are thought to be the duration of coma, the patient’s clinical status prior to dialysis, and the ammonia removal rate. In this review, we discuss the various dialytic modalities used for ammonia clearance as well as the thresholds for initiating dialysis and the better strategy ensures rapid patient protection from cerebral edema and herniation induced by hyperammonemia.
References
1.
Westrope C, Morris K, Burford D, Morrison G. Continuous hemofiltration in the control of neonatal hyperammonemia: a 10-year experience.
Pediatr Nephrol
. 2010 Sep;25(9):1725–30.2.
Clay AS, Hainline BE. Hyperammonemia in the ICU.
Chest
. 2007 Oct;132(4):1368–78.3.
Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure.
Hepatology
. 2007 Dec;46(6):1844–52.4.
Cordoba J, Blei AT, Mujais S. Determinants of ammonia clearance by hemodialysis.
Artif Organs
. 1996 Jul;20(7):800–3.5.
Cooper AJ, Nieves E, Coleman AE, Filc-DeRicco S, Gelbard AS. Short-term metabolic fate of [13N]ammonia in rat liver in vivo.
J Biol Chem
. 1987 Jan;262(3):1073–80.6.
Siegel NJ, Brown RS. Peritoneal clearance of ammonia and creatinine in a neonate.
J Pediatr
. 1973 Jun;82(6):1044–6.7.
Rutledge SL, Havens PL, Haymond MW, McLean RH, Kan JS, Brusilow SW. Neonatal hemodialysis: effective therapy for the encephalopathy of inborn errors of metabolism.
J Pediatr
. 1990 Jan;116(1):125–8.8.
Wiegand C, Thompson T, Bock GH, Mathis RK, Kjellstrand CM, Mauer SM. The management of life-threatening hyperammonemia: a comparison of several therapeutic modalities.
J Pediatr
. 1980 Jan;96(1):142–4.9.
Pela I, Seracini D, Donati MA, Lavoratti G, Pasquini E, Materassi M. Peritoneal dialysis in neonates with inborn errors of metabolism: is it really out of date?
Pediatr Nephrol
. 2008 Jan;23(1):163–8.10.
Wong KY, Wong SN, Lam SY, Tam S, Tsoi NS. Ammonia clearance by peritoneal dialysis and continuous arteriovenous hemodiafiltration.
Pediatr Nephrol
. 1998 Sep;12(7):589–91.11.
Ring E, Zobel G, Stöckler S. Clearance of toxic metabolites during therapy for inborn errors of metabolism.
J Pediatr
. 1990 Aug;117(2 Pt 1):349–50.12.
Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders.
Orphanet J Rare Dis
. 2012 May;7(1):32.13.
Schaefer F, Straube E, Oh J, Mehls O, Mayatepek E. Dialysis in neonates with inborn errors of metabolism.
Nephrol Dial Transplant
. 1999 Apr;14(4):910–8.14.
Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, et al. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators.
Pediatr Nephrol
. 2001 Nov;16(11):862–7.15.
Rajpoot DK, Gargus JJ. Acute hemodialysis for hyperammonemia in small neonates.
Pediatr Nephrol
. 2004 Apr;19(4):390–5.16.
Arbeiter AK, Kranz B, Wingen AM, Bonzel KE, Dohna-Schwake C, Hanssler L, et al. Continuous venovenous haemodialysis (CVVHD) and continuous peritoneal dialysis (CPD) in the acute management of 21 children with inborn errors of metabolism.
Nephrol Dial Transplant
. 2010 Apr;25(4):1257–65.17.
Picca S, Dionisi-Vici C, Bartuli A, De Palo T, Papadia F, Montini G, et al. Short-term survival of hyperammonemic neonates treated with dialysis.
Pediatr Nephrol
. 2015 May;30(5):839–47.18.
Cavagnaro Santa María F, Roque Espinosa J, Guerra Hernández P. Continuous venovenous hemofiltration in neonates with hyperammonemia. A case series.
Rev Chil Pediatr
. 2018 Feb;89(1):74–8.19.
Picca S, Bartuli A, Dionisi-Vici C. Medical management and dialysis therapy for the infant with an inborn error of metabolism.
Semin Nephrol
. 2008 Sep;28(5):477–80.20.
Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.
N Engl J Med
. 2007 May;356(22):2282–92.21.
Lai YC, Huang HP, Tsai IJ, Tsau YK. High-volume continuous venovenous hemofiltration as an effective therapy for acute management of inborn errors of metabolism in young children.
Blood Purif
. 2007;25(4):303–8.22.
Chan WK, But WM, Law CW. Ammonia detoxification by continuous venovenous haemofiltration in an infant with urea cycle defect.
Hong Kong Med J
. 2002 Jun;8(3):207–10.23.
Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL. High-dose continuous renal replacement therapy for neonatal hyperammonemia.
Pediatr Nephrol
. 2013 Jun;28(6):983–6.24.
McBryde KD, Kershaw DB, Bunchman TE, Maxvold NJ, Mottes TA, Kudelka TL, et al. Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism.
J Pediatr
. 2006 Jun;148(6):770–8.25.
Hanudel M, Avasare S, Tsai E, Yadin O, Zaritsky J. A biphasic dialytic strategy for the treatment of neonatal hyperammonemia.
Pediatr Nephrol
. 2014 Feb;29(2):315–20.26.
Slack AJ, Auzinger G, Willars C, Dew T, Musto R, Corsilli D, et al. Ammonia clearance with haemofiltration in adults with liver disease.
Liver Int
. 2014 Jan;34(1):42–8.27.
Cardoso FS, Gottfried M, Tujios S, Olson JC, Karvellas CJ; US Acute Liver Failure Study Group. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure.
Hepatology
. DOI: 10.1002/hep.29488.28.
Mattson LR, Lindor NM, Goldman DH, Goodwin JT, Groover RV, Vockley J. Central pontine myelinolysis as a complication of partial ornithine carbamoyl transferase deficiency.
Am J Med Genet
. 1995 Jun;60(3):210–3.© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
